^
    Evidence Level:
    Sensitive: A1 - Approval

    [FGFR2 mutation-Urothelial Cancer-erdafitinib]

    Source:
    FDA
    Test:

    therascreen® FGFR RGQ RT-PCR Kit

    Excerpt:
    BALVERSA is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has...susceptible FGFR3 or FGFR2 genetic alterations and...progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
    Evidence Level:
    Sensitive: A1 - Approval

    [FGFR3 mutation-Urothelial Cancer-erdafitinib]

    Source:
    FDA
    Test:

    therascreen® FGFR RGQ RT-PCR Kit

    Excerpt:
    BALVERSA is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has...susceptible FGFR3 or FGFR2 genetic alterations and...progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.